Allogene best positioned among next gen cell therapies, says Piper Jaffray

After conducting nearly 30 hours’ worth of interviews with C-level management at numerous companies, Piper Jaffray analyst Tyler Van Buren says Allogene Therapeutics is best positioned among the wave of next generation cell therapies. Allogene is implementing changes on a “methodical, step-by-step basis that could enable a higher quality and more homogenous product,” Van Buren tells investors in a research note. He keeps an Overweight rating on the shares with a $50 price target.

https://thefly.com/landingPageNews.php?id=2898769